Skip to content 
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia. more
| Time Frame | CUVL | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -21.03% | -1.98% | 0.5% |
| 1-Month Return | -12.13% | 2.33% | 3.86% |
| 3-Month Return | -15.5% | 13.44% | 1.92% |
| Jun '22 | Jun '23 | Jun '24 | Jun '25 | |||
|---|---|---|---|---|---|---|
| Total Revenue | 65.72M | 78.32M | 88.18M | 95.02M | [{"date":"2022-06-30","value":69.17,"profit":true},{"date":"2023-06-30","value":82.43,"profit":true},{"date":"2024-06-30","value":92.8,"profit":true},{"date":"2025-06-30","value":100,"profit":true}] | |
| Cost of Revenue | 10.48M | 8.79M | 10.08M | 15.88M | [{"date":"2022-06-30","value":66.02,"profit":true},{"date":"2023-06-30","value":55.35,"profit":true},{"date":"2024-06-30","value":63.48,"profit":true},{"date":"2025-06-30","value":100,"profit":true}] | |
| Gross Profit | 55.24M | 69.53M | 78.10M | 79.14M | [{"date":"2022-06-30","value":69.8,"profit":true},{"date":"2023-06-30","value":87.86,"profit":true},{"date":"2024-06-30","value":98.69,"profit":true},{"date":"2025-06-30","value":100,"profit":true}] | |
| Gross Margin | 84.05% | 88.78% | 88.57% | 83.29% | [{"date":"2022-06-30","value":94.67,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":99.76,"profit":true},{"date":"2025-06-30","value":93.82,"profit":true}] | |
| Operating Expenses | - | - | - | - | [{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true}] | |
| Operating Income | 35.33M | 44.10M | 48.01M | 45.73M | [{"date":"2022-06-30","value":73.6,"profit":true},{"date":"2023-06-30","value":91.87,"profit":true},{"date":"2024-06-30","value":100,"profit":true},{"date":"2025-06-30","value":95.27,"profit":true}] | |
| Total Non-Operating Income/Expense | (1.01M) | 1.48M | 2.67M | 5.82M | [{"date":"2022-06-30","value":-17.34,"profit":false},{"date":"2023-06-30","value":25.37,"profit":true},{"date":"2024-06-30","value":45.93,"profit":true},{"date":"2025-06-30","value":100,"profit":true}] | |
| Pre-Tax Income | 34.32M | 45.58M | 50.68M | 51.55M | [{"date":"2022-06-30","value":66.57,"profit":true},{"date":"2023-06-30","value":88.41,"profit":true},{"date":"2024-06-30","value":98.3,"profit":true},{"date":"2025-06-30","value":100,"profit":true}] | |
| Income Taxes | - | - | - | - | [{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true}] | |
| Income After Taxes | - | - | - | - | [{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true}] | |
| Income From Continuous Operations | 20.88M | 30.60M | 35.64M | 36.17M | [{"date":"2022-06-30","value":57.72,"profit":true},{"date":"2023-06-30","value":84.61,"profit":true},{"date":"2024-06-30","value":98.52,"profit":true},{"date":"2025-06-30","value":100,"profit":true}] | |
| Income From Discontinued Operations | - | - | - | - | [{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true}] | |
| Net Income | 20.88M | 30.60M | 35.64M | 36.17M | [{"date":"2022-06-30","value":57.72,"profit":true},{"date":"2023-06-30","value":84.61,"profit":true},{"date":"2024-06-30","value":98.52,"profit":true},{"date":"2025-06-30","value":100,"profit":true}] | |
| EPS (Diluted) | - | - | - | - | [{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true}] | |
These ratios help you determine the liquidity of the company. Higher is better.
| CUVL | |
|---|---|
| Current Ratio | 9.66 |
| Quick Ratio | 9.34 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| CUVL | |
|---|---|
| ROA (LTM) | 10.62% |
| ROE (LTM) | 13.96% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| CUVL | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.11 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.89 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| CUVL | |
|---|---|
| Trailing PE | 16.51 |
| Forward PE | 12.95 |
| P/S (TTM) | 3.55 |
| P/B | 2.16 |
| EV/R | 3.09 |
| EV/Ebitda | 5.92 |
Clinuvel Pharmaceuticals Limited American Depositary Shares (CUVL) share price today is $6.01
Yes, Indians can buy shares of Clinuvel Pharmaceuticals Limited American Depositary Shares (CUVL) on Vested. To buy
Yes, you can purchase fractional shares of Clinuvel Pharmaceuticals Limited American Depositary Shares (CUVL) via the Vested app. You can start investing in Clinuvel Pharmaceuticals Limited American Depositary Shares (CUVL) with a minimum investment of $1.
You can invest in shares of Clinuvel Pharmaceuticals Limited American Depositary Shares (CUVL) via Vested in three simple steps:
The 52-week high price of Clinuvel Pharmaceuticals Limited American Depositary Shares (CUVL) is $8.2. The 52-week low price of Clinuvel Pharmaceuticals Limited American Depositary Shares (CUVL) is $6.12.
The price-to-earnings (P/E) ratio of Clinuvel Pharmaceuticals Limited American Depositary Shares (CUVL) is 16.5122
The price-to-book (P/B) ratio of Clinuvel Pharmaceuticals Limited American Depositary Shares (CUVL) is 2.16
The dividend yield of Clinuvel Pharmaceuticals Limited American Depositary Shares (CUVL) is 0.00%
The market capitalization of Clinuvel Pharmaceuticals Limited American Depositary Shares (CUVL) is $310.64M
The stock symbol (or ticker) of Clinuvel Pharmaceuticals Limited American Depositary Shares is CUVL
Consider the share price of Clinuvel Pharmaceuticals Limited American Depositary Shares as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Clinuvel Pharmaceuticals Limited American Depositary Shares has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Clinuvel Pharmaceuticals Limited American Depositary Shares shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Clinuvel Pharmaceuticals Limited American Depositary Shares stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Clinuvel Pharmaceuticals Limited American Depositary Shares and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Clinuvel Pharmaceuticals Limited American Depositary Shares stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
